Anika Therapeutics Stock Five Year Return
| ANIK Stock | USD 17.28 0.35 2.07% |
Anika Therapeutics fundamentals help investors to digest information that contributes to Anika Therapeutics' financial success or failures. It also enables traders to predict the movement of Anika Stock. The fundamental analysis module provides a way to measure Anika Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anika Therapeutics stock.
Anika |
Anika Therapeutics Company Five Year Return Analysis
Anika Therapeutics' Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
According to the company disclosure, Anika Therapeutics has a Five Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
Anika Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0401 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.64) % | ||||
| Current Valuation | 213.12 M | ||||
| Shares Outstanding | 14.65 M | ||||
| Shares Owned By Insiders | 3.40 % | ||||
| Shares Owned By Institutions | 89.79 % | ||||
| Number Of Shares Shorted | 402.31 K | ||||
| Price To Earning | 42.30 X | ||||
| Price To Book | 1.38 X | ||||
| Price To Sales | 1.54 X | ||||
| Revenue | 166.66 M | ||||
| Gross Profit | 80.23 M | ||||
| EBITDA | (11.23 M) | ||||
| Net Income | (82.67 M) | ||||
| Cash And Equivalents | 87.78 M | ||||
| Cash Per Share | 6.01 X | ||||
| Total Debt | 29.04 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 6.37 X | ||||
| Book Value Per Share | 12.24 X | ||||
| Cash Flow From Operations | (1.79 M) | ||||
| Short Ratio | 5.20 X | ||||
| Earnings Per Share | (6.64) X | ||||
| Price To Earnings To Growth | 3.60 X | ||||
| Target Price | 26.5 | ||||
| Number Of Employees | 357 | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 253.08 M | ||||
| Total Asset | 270.63 M | ||||
| Retained Earnings | 128.05 M | ||||
| Working Capital | 132.25 M | ||||
| Current Asset | 176.43 M | ||||
| Current Liabilities | 17.28 M | ||||
| Net Asset | 270.63 M |
About Anika Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anika Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anika Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anika Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Anika Therapeutics Piotroski F Score and Anika Therapeutics Altman Z Score analysis. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.